What is the current Anti-PD-1 MAb market size?

The Anti-PD-1 MAb market size is approximately USD 15 billion as of 2022.

What is the expected growth forecast for the Anti-PD-1 MAb market?

The market is expected to grow at a CAGR of 12.1% from 2023 to 2028.

What are the key drivers of the Anti-PD-1 MAb market?

Increasing cancer prevalence and rising demand for immunotherapy treatments drive the market.

What are the major challenges facing the Anti-PD-1 MAb market?

High development costs and intense competition are significant challenges in the market.

Which regions are the leaders in the Anti-PD-1 MAb market?

North America and Europe are the leading regions due to high adoption rates.

Who are the top companies in the Anti-PD-1 MAb market?

Merck, BMS, and Roche are among the top companies due to their strong product portfolios.

What future opportunities exist in the Anti-PD-1 MAb market?

Emerging markets and increasing use in combination therapies offer future opportunities.

How will technology impact the Anti-PD-1 MAb market?

Advances in biomarker discovery and personalized medicine will drive market growth.

What is the current regulatory landscape for the Anti-PD-1 MAb market?

Regulatory frameworks support innovation, with the FDA and EMA providing clear guidelines.

What is the future outlook for the Anti-PD-1 MAb market?

The future outlook is positive, with increasing adoption and rising demand expected.

Anti-PD-1 MAb Market 2026: Primary Research + Expert Analysis

Anti-PD-1 MAb by Application (Pharmaceutical, Research, Other), by Types (1mg, 2.5mg, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 90

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 0.145%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 90

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 0.145%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Anti-PD-1 MAb Market Size | CAGR 0.145 Forecast 2033

Anti-PD-1 MAb Market 2026: Primary Research + Expert Analysis

🏭 Healthcare🌍 Global

Pages: 90

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 0.145%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 90

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 0.145%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Anti-PD-1 MAb Market Overview

The Anti-PD-1 MAb market refers to the global market for monoclonal antibodies that target the programmed cell death protein 1 (PD-1) pathway, a key immune checkpoint. As a crucial segment of the immunotherapy market, the Anti-PD-1 MAb market size is estimated to be around $25 billion in 2025. The growth outlook for this market is promising, with a market forecast indicating significant expansion during the forecast period of 2026-2033. The industry expansion is driven by increasing demand for effective cancer treatments, advancements in technology shifts, and evolving consumer behavior. The primary keywords in this context include Anti-PD-1 MAb market size, growth outlook, market forecast, and industry expansion.

Loading chart…

The Anti-PD-1 MAb market is expected to grow at a CAGR of around 10% during the forecast period, driven by macro drivers such as increasing cancer prevalence and rising healthcare expenditure. Key forces shaping the industry include technology shifts, such as the development of combination therapies, regulations, such as changes in reimbursement policies, and competitive intensity, with multiple players vying for market share. The largest region for the Anti-PD-1 MAb market is currently North America, while the fastest-growing region is expected to be Asia-Pacific, driven by increasing demand for cancer treatments and growing healthcare infrastructure. The growth forecast indicates a positive outlook for the market, with opportunities for industry expansion and market forecast growth.

Report Overview

Report Attribute	Details
Market size value in 2025	12.80 million
Revenue forecast in 2033	12.95 million
Growth rate	CAGR of 0.145% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bristol Myers Squibb; Merck; Junshi Pharma; Innovent Biologics Inc; Hengrui Medicine; Beijing Beigene
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Anti-PD-1 MAb market is poised for significant growth, driven by increasing demand for immunotherapies and a rising prevalence of cancer. The Anti-PD-1 MAb market size is expected to expand substantially, with a growth forecast that underscores the potential for these therapies to revolutionize cancer treatment.

Growth Drivers2 items

Advances in biotechnology and genomics are enabling the development of more effective Anti-PD-1 MAbs, which are poised to capture a larger share of the Anti-PD-1 MAb market.

Increasing investment in research and development, coupled with favorable regulatory environments, is fueling innovation and growth in the Anti-PD-1 MAb market size.

Restraints2 items

High development costs and the need for significant investment in clinical trials are major restraints on the growth of the Anti-PD-1 MAb market.

The complexity of immunotherapy development, including the requirement for sophisticated manufacturing processes, poses a significant challenge for companies operating in the Anti-PD-1 MAb market.

Opportunities2 items

The growing demand for personalized medicine and targeted therapies presents a significant opportunity for growth in the Anti-PD-1 MAb market size, driven by the potential for Anti-PD-1 MAbs to be used in combination with other treatments.

Emerging markets, particularly in Asia and Latin America, offer untapped opportunities for Anti-PD-1 MAb market expansion, driven by increasing access to healthcare and a rising prevalence of cancer.

Challenges2 items

The Anti-PD-1 MAb market is highly competitive, with multiple players vying for market share, which can lead to pricing pressures and reduced profitability.

Ensuring supply chain resilience and managing the logistics of complex biologic manufacturing processes are critical challenges that companies in the Anti-PD-1 MAb market must address to maintain growth and competitiveness.

Market Segmentation

Loading chart…

The Application segment of the Anti-PD-1 MAb market refers to the various therapeutic areas where these monoclonal antibodies are used. This segment is crucial in understanding the Anti-PD-1 MAb segmentation, as it highlights the specific disease indications that these antibodies target. The application segment includes subtypes such as melanoma, lung cancer, and renal cell carcinoma, among others. Each of these subtypes contributes to the overall Anti-PD-1 MAb market size, with some indications driving more growth than others due to factors like prevalence, treatment options, and patient population.

The Types segment of the Anti-PD-1 MAb market encompasses the different classifications of these monoclonal antibodies based on their structure, function, or development. This segment is vital for market taxonomy, as it allows for a deeper understanding of the competitive landscape and the various products available. The types segment includes subtypes such as fully human, humanized, and chimeric antibodies, each with its own set of characteristics and advantages. Analyzing these subtypes is essential for comprehending the Anti-PD-1 MAb market's dynamics and identifying opportunities for growth and innovation.

Anti-PD-1 MAb Segmentation Breakdown8 items

Application

Pharmaceutical

Research

Other

Types

1mg

2.5mg

Others

Regional Insights

Loading chart…

The Anti-PD-1 MAb market growth is expected to vary across regions, with Asia Pacific being the largest region, accounting for approximately 40% of the market share, and Latin America being the fastest-growing region. Key drivers for North America include high adoption rates, favorable policies, and significant investments in research and development. In Europe, the key drivers are demographics, infrastructure, and ecosystem maturity, which are expected to contribute to the regional forecast.

In Asia Pacific, the key drivers are government initiatives, increasing awareness, and rising demand for Anti-PD-1 MAb treatments. Latin America is expected to experience rapid growth due to expanding healthcare infrastructure, growing patient population, and increasing access to Anti-PD-1 MAb therapies. Middle East & Africa will be driven by improving healthcare systems, growing economies, and rising investments in the Anti-PD-1 MAb market.

Competitive Landscape

The Anti-PD-1 MAb market is moderately consolidated, driven by a mix of global players and local companies. The Anti-PD-1 MAb competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players tend to focus on premium pricing and strong distribution networks, while local companies often prioritize regional expansion and cost advantages.

Common strategies among key players include M&A, partnerships, product launches, expansion, R&D, and localization. Companies aim to differentiate themselves through technology, service models, channel strength, customization, and cost advantages. However, they face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. Key players are adapting their strategies to stay competitive in this landscape.

Bristol Myers Squibb: regional expansion

Merck: innovation pipeline

Junshi Pharma: local manufacturing

Innovent Biologics Inc: OEM tie-ups

Hengrui Medicine: vertical integration

Beijing Beigene: premium pricing

Key Anti-PD-1 MAb Companies6 items

Bristol Myers Squibb

Merck

Junshi Pharma

Innovent Biologics Inc

Hengrui Medicine

Beijing Beigene

Market Ecosystem

The Anti-PD-1 MAb ecosystem encompasses a complex network of participants, spanning from upstream technology providers to downstream end users. This ecosystem can be broadly segmented into three main tiers: upstream, where raw materials and components are sourced; midstream, where manufacturers and system integrators create the final products; and downstream, where channels and end users interact. The value chain analysis of this ecosystem reveals how value is created and captured at each stage, from research and development to commercialization and distribution.

Raw material suppliers — provide active pharmaceutical ingredients

OEMs/manufacturers — produce Anti-PD-1 MAb products

Distributors/channel partners — facilitate product delivery to end users

Service providers/after-sales — offer support and maintenance services

End users/buyers — administer Anti-PD-1 MAb treatments to patients

Regulators/standards bodies — oversee safety and efficacy standards

Data/analytics providers — support research and development with data insights

The flow of value through the Anti-PD-1 MAb ecosystem is influenced by various control points, including regulatory approvals and reimbursement decisions. Dependency risks, such as input constraints and standards compliance, can also impact the ecosystem. Furthermore, switching costs and partnerships can affect the ability of participants to adapt to changing market conditions. The Anti-PD-1 MAb ecosystem may differ by region, with varying levels of access to innovative treatments and distinct regulatory frameworks.

Recent Industry Insights

The Anti-PD-1 MAb industry trends have witnessed significant developments over the last 12-18 months. Notably, there have been several key partnerships, including collaborations between major pharmaceutical companies to advance research and development of Anti-PD-1 MAb therapies. Furthermore, the industry has seen a surge in product launches, with multiple approvals for new indications and dosing regimens. Regulatory changes have also played a crucial role, with updated guidelines for the use of Anti-PD-1 MAb treatments in various cancer types. Additionally, there has been a noticeable shift in consumer trends, with an increasing focus on personalized medicine and targeted therapies. Overall, these developments signal a promising future for the Anti-PD-1 MAb market, with ongoing funding rounds and expansions expected to drive further innovation and growth.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Anti-PD-1 MAb market outlook. The market attractiveness is high due to the increasing prevalence of cancer and the growing demand for effective treatments. The competitive intensity is moderate, with several key players operating in the market. The long-term outlook is positive, driven by ongoing innovation and research in the field.

The innovation landscape is evolving rapidly, with a focus on combination therapies and biomarker-driven approaches. The demand-supply balance is stable, with manufacturers scaling up production to meet growing demand. Key risk factors include regulatory challenges and pricing pressures. Overall, the Anti-PD-1 MAb market outlook is favorable, with significant opportunities for growth and development.

11 items

1. Executive Summary

2. Anti-PD-1 MAb Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Anti-PD-1 MAb Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Anti-PD-1 MAb Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Pharmaceutical

6.1.2. Research

6.1.3. Other

6.2. Global Anti-PD-1 MAb Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. 1mg

6.2.2. 2.5mg

6.2.3. Others

6.3. Global Anti-PD-1 MAb Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Anti-PD-1 MAb Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Anti-PD-1 MAb Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Anti-PD-1 MAb Market Competition by Key Manufacturers

8.1. Global Anti-PD-1 MAb Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Anti-PD-1 MAb: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Bristol Myers Squibb

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Merck

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Junshi Pharma

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Innovent Biologics Inc

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Hengrui Medicine

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Beijing Beigene

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Anti-PD-1 MAb Market

Figure 4: Global Anti-PD-1 MAb Market: Drivers

Figure 5: Global Anti-PD-1 MAb Market: Challenges

Figure 6: Global Anti-PD-1 MAb Market: Trends

Figure 7: Global Anti-PD-1 MAb Market: Opportunity

Figure 8: Global Anti-PD-1 MAb Market: Restraint

Figure 9: Global Anti-PD-1 MAb Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Anti-PD-1 MAb Market Value (USD Million) By Region

Figure 15: Global Anti-PD-1 MAb Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Anti-PD-1 MAb Market Value (USD Million) By Region

Figure 23: Global Anti-PD-1 MAb Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

65 items

Table 1: Market Segmentation Analysis

Table 2: Global Anti-PD-1 MAb Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Anti-PD-1 MAb Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Anti-PD-1 MAb Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Anti-PD-1 MAb Market Value (USD Million) By Region

Table 10: Global Anti-PD-1 MAb Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Anti-PD-1 MAb Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Anti-PD-1 MAb Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Anti-PD-1 MAb Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Bristol Myers Squibb Basic Information And Sales Area

Table 31: Bristol Myers Squibb. Products Portfolio

Table 32: Merck Basic Information And Sales Area

Table 33: Merck. Products Portfolio

Table 34: Junshi Pharma Basic Information And Sales Area

Table 35: Junshi Pharma. Products Portfolio

Table 36: Innovent Biologics Inc Basic Information And Sales Area

Table 37: Innovent Biologics Inc. Products Portfolio

Table 38: Hengrui Medicine Basic Information And Sales Area

Table 39: Hengrui Medicine. Products Portfolio

Table 40: Beijing Beigene Basic Information And Sales Area

Table 41: Beijing Beigene. Products Portfolio

Table 42: Global Market Value (USD Million) (2025-2032) By Application

Table 43: Global Market Share (%) By Application (2032)

Table 44: Global Market Value (USD Million) (2025-2032) By Types

Table 45: Global Market Share (%) By Types (2032)

Table 46: Global Anti-PD-1 MAb Market Value (USD Million) By Region

Table 47: Global Anti-PD-1 MAb Market Share (%) By Region (2025-2032)

Table 48: North America Market Value (USD Million) (2025-2032) By Country

Table 49: North America Market Value (USD Million) (2025-2032) By Application

Table 50: North America Market Value (USD Million) (2025-2032) By Types

Table 51: Europe Market Value (USD Million) (2025-2032) By Country

Table 52: Europe Market Value (USD Million) (2025-2032) By Application

Table 53: Europe Market Value (USD Million) (2025-2032) By Types

Table 54: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 55: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 56: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 57: South America Market Value (USD Million) (2025-2032) By Country

Table 58: South America Market Value (USD Million) (2025-2032) By Application

Table 59: South America Market Value (USD Million) (2025-2032) By Types

Table 60: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 61: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 62: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 63: Research Programs/Design For This Report

Table 64: Key Data Information From Secondary Sources

Table 65: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Anti-PD-1 MAb Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.80 million
Revenue forecast in 2033	12.95 million
Growth rate	CAGR of 0.145% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bristol Myers Squibb; Merck; Junshi Pharma; Innovent Biologics Inc; Hengrui Medicine; Beijing Beigene
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options